Serum MIF in Acute Kidney Injury

NCT02352506 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2023-03-15

No results posted yet for this study

Summary

Acute kidney injury (AKI) is a common complication in critical care patients. Currently no parameters are available for early prognosis of AKI. Macrophage migration inhibitory factor (MIF) has been associated with AKI in clinical studies. The aim of this study is to evaluate the time course of MIF concentrations in patients with AKI.

Conditions

Interventions

OTHER

Blood draw for measurement of MIF

Observational study, no intervention

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2019-11-30
Completion
2023-01-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02352506 on ClinicalTrials.gov